It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The incidence of early-onset colorectal cancer (eoCRC) is rising, and its pathogenesis is not completely understood. We hypothesized that machine learning utilizing paired tissue microbiome and plasma metabolome features could uncover distinct host-microbiome associations between eoCRC and average-onset CRC (aoCRC). Individuals with stages I–IV CRC (n = 64) were categorized as eoCRC (age ≤ 50, n = 20) or aoCRC (age ≥ 60, n = 44). Untargeted plasma metabolomics and 16S rRNA amplicon sequencing (microbiome analysis) of tumor tissue were performed. We fit DIABLO (Data Integration Analysis for Biomarker Discovery using Latent variable approaches for Omics studies) to construct a supervised machine-learning classifier using paired multi-omics (microbiome and metabolomics) data and identify associations unique to eoCRC. A differential association network analysis was also performed. Distinct clustering patterns emerged in multi-omic dimension reduction analysis. The metabolomics classifier achieved an AUC of 0.98, compared to AUC 0.61 for microbiome-based classifier. Circular correlation technique highlighted several key associations. Metabolites glycerol and pseudouridine (higher abundance in individuals with aoCRC) had negative correlations with Parasutterella, and Ruminococcaceae (higher abundance in individuals with eoCRC). Cholesterol and xylitol correlated negatively with Erysipelatoclostridium and Eubacterium, and showed a positive correlation with Acidovorax with higher abundance in individuals with eoCRC. Network analysis revealed different clustering patterns and associations for several metabolites e.g.: urea cycle metabolites and microbes such as Akkermansia. We show that multi-omics analysis can be utilized to study host-microbiome correlations in eoCRC and demonstrates promising biomarker potential of a metabolomics classifier. The distinct host-microbiome correlations for urea cycle in eoCRC may offer opportunities for therapeutic interventions.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details



1 Cleveland Clinic, Department of Hematology-Oncology, Taussig Cancer Institute, Cleveland, USA (GRID:grid.239578.2) (ISNI:0000 0001 0675 4725); Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910)
2 Cleveland Clinic, Microbial Sequencing & Analytics Resource (MSAAR), Lerner Research Institute, Cleveland, USA (GRID:grid.239578.2) (ISNI:0000 0001 0675 4725)
3 Cleveland Clinic, Department of Hematology-Oncology, Taussig Cancer Institute, Cleveland, USA (GRID:grid.239578.2) (ISNI:0000 0001 0675 4725)
4 Cleveland Clinic, Department of Quantitative Health Sciences, Lerner Research Institute, Cleveland, USA (GRID:grid.239578.2) (ISNI:0000 0001 0675 4725); Cleveland Clinic, Center for Quantitative Metabolic Research, Cleveland, USA (GRID:grid.239578.2) (ISNI:0000 0001 0675 4725)
5 Cleveland Clinic, Department of Surgery, Cleveland, USA (GRID:grid.239578.2) (ISNI:0000 0001 0675 4725)
6 Case Comprehensive Cancer Center, Cleveland, USA (GRID:grid.239578.2) (ISNI:0000 0004 0455 2742); University Hospital Seidman Cancer Center, Department of Hematology-Oncology, Cleveland, USA (GRID:grid.473817.e) (ISNI:0000 0004 0418 9795)
7 Cleveland Clinic, Department of Hematology-Oncology, Taussig Cancer Institute, Cleveland, USA (GRID:grid.239578.2) (ISNI:0000 0001 0675 4725); Case Comprehensive Cancer Center, Cleveland, USA (GRID:grid.239578.2) (ISNI:0000 0004 0455 2742); Cleveland Clinic, Center for Young-Onset Colorectal Cancer, Cleveland, USA (GRID:grid.239578.2) (ISNI:0000 0001 0675 4725)
8 Cleveland Clinic, Center for Young-Onset Colorectal Cancer, Cleveland, USA (GRID:grid.239578.2) (ISNI:0000 0001 0675 4725); Cleveland Clinic, Genomic Medicine Institute, Lerner Research Institute, Cleveland, USA (GRID:grid.239578.2) (ISNI:0000 0001 0675 4725); Case Comprehensive Cancer Center, Population and Cancer Prevention Program, Cleveland, USA (GRID:grid.239578.2) (ISNI:0000 0004 0455 2742)
9 Case Comprehensive Cancer Center, Cleveland, USA (GRID:grid.239578.2) (ISNI:0000 0004 0455 2742); Cleveland Clinic, Center for Young-Onset Colorectal Cancer, Cleveland, USA (GRID:grid.239578.2) (ISNI:0000 0001 0675 4725); Cleveland Clinic, Department of Colorectal Surgery, Digestive Disease & Surgery Institute, Cleveland, USA (GRID:grid.239578.2) (ISNI:0000 0001 0675 4725)